KalVista Pharmaceuticals, Inc.
KALV
$11.85
$0.100.85%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -48.59% | -16.97% | -67.11% | -52.86% | -59.75% |
| Total Depreciation and Amortization | 12.50% | 19.18% | 10.63% | 15.23% | 16.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 334.86% | -99.51% | 338.43% | -42.80% | -11.63% |
| Change in Net Operating Assets | -103.42% | -30.53% | 641.96% | -94.41% | 45.25% |
| Cash from Operations | -35.51% | -167.22% | -18.53% | -99.96% | -50.47% |
| Capital Expenditure | -1,280.95% | -1,773.33% | -26.32% | -5,300.00% | -250.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.04% | 97.59% | 227.80% | 70.81% | 89.53% |
| Cash from Investing | -42.79% | 97.36% | 227.08% | 70.45% | 89.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -57.03% | -98.09% | 19,809.51% | 130.47% | 1,370.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -94.71% | -- | -- | -- |
| Cash from Financing | 673.67% | -96.90% | 53,341.20% | 130.47% | 1,370.59% |
| Foreign Exchange rate Adjustments | 2,227.35% | 4,645.95% | -101.13% | 167.61% | 39.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12,486.44% | -508.44% | 465.10% | 17.88% | 100.86% |